Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10328396" target="_blank" >RIV/00216208:11110/16:10328396 - isvavai.cz</a>
Result on the web
<a href="http://www.neurology.org/content/87/14/1464.full" target="_blank" >http://www.neurology.org/content/87/14/1464.full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/WNL.0000000000003169" target="_blank" >10.1212/WNL.0000000000003169</a>
Alternative languages
Result language
angličtina
Original language name
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS
Original language description
Objective: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon beta-1a (SC IFN-beta-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS). Methods: The impact of alemtuzumab 12 mg vs SC IFN-beta-1a 44 mg on MRI measures was evaluated in patients with RRMS who were treatment-naive (CARE-MS I) or who had an inadequate response, defined as at least one relapse, to prior therapy (CARE-MS II). Results: Both treatments prevented T2-hyperintense lesion volume increases from baseline. Alemtuzumab was more effective than SC IFN-beta-1a on most lesion-based endpoints in both studies (p < 0.05), including decreased risk of new/enlarging T2 lesions over 2 years and gadolinium-enhancing lesions at year 2. Reduced risk of new T1 lesions (p < 0.0001) and gadolinium-enhancing lesion conversion to T1-hypointense black holes (p = 0.0078) were observed with alemtuzumab vs SC IFN-beta-1a in CARE-MS II. Alemtuzumab slowed brain volume loss over 2 years in CARE-MS I (p, 0.0001) and II (p = 0.012) vs SC IFN-beta-1a. Conclusions: Alemtuzumab demonstrated greater efficacy than SC IFN-beta-1a on MRI endpoints in active RRMS. The superiority of alemtuzumab was more prominent during the second year of both studies. These findings complement the superior clinical efficacy of alemtuzumab over SC IFN-beta-1a in RRMS. ClinicalTrials.gov identifier: NCT00530348 and NCT00548405. Classification of evidence: The results reported here provide Class I evidence that, for patients with active RRMS, alemtuzumab is superior to SC IFN-beta-1a on multiple MRI endpoints.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurology
ISSN
0028-3878
e-ISSN
—
Volume of the periodical
87
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
1464-1472
UT code for WoS article
000385656700014
EID of the result in the Scopus database
2-s2.0-84989942285